Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual patient-level data from the pivotal, phase II, single-arm KarMMa trial (NCT03361748) and aggregate-level data from MAMMOTH, the largest independent observational study of CC in heavily pretreated RRMM patients. Results: Ide-cel improved overall response rate (odds ratio: 5.30; 95% CI: 2.96–9.51), progression-free survival (hazard ratio: 0.50; 95% CI: 0.36–0.70) and overall survival (hazard ratio: 0.37; 95% CI: 0.25–0.56) versus CC. Conclusion: These results suggest ide-cel offers improvements in clinical outcomes relative to CC in this heavily pretreated RRMM population.
Supplementary Material
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
World Health Organization, International Agency for Research on Cancer (IARC). GLOBOCAN 2020: estimated multiple myeloma incidence, mortality and prevalence worldwide in 2020. IARC, Lyon, France (December 2020). Available at: https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf
2.
Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic health record data. Leuk. Lymphoma 62(2), 377–386 (2021).
3.
Fonseca R, Abouzaid S, Bonafede M et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia 31(9), 1915–1921 (2017).
4.
Gandhi UH, Cornell RF, Lakshman A et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33(9), 2266–2275 (2019).
•• Details outcomes of patients with multiple myeloma refractory to anti-CD38 monoclonal antibodies (MAMMOTH).
5.
Munshi NC, Anderson LD, Shah N et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384(8), 705–716 (2021).
•• Describes efficacy and safety data for patients with relapsed and refractory multiple myeloma treated with idecabtagene vicleucel in the pivotal, phase II KarMMa trial.
6.
Anderson LD, Munshi NC, Shah N et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J. Clin. Oncol. 39(Suppl. 15), S8016 (2021).
• Outlines updated efficacy and safety results from the KarMMa trial.
7.
Celgene. ABECMA (idecabtagene vicleucel). Celgene Corporation, a Bristol Myers Squibb Company, Summit, NJ, USA (2021). Available at: https://packageinserts.bms.com/pi/pi_abecma.pdf
8.
Celgene. Abecma (idecabtagene vicleucel) [summary of product characteristics]. Celgene Europe B.V, Utrecht, Netherlands (25 August 2021). Available at: www.ema.europa.eu/documents/product-information/abecma-epar-product-information_en.pdf
9.
Karyopharm. XPOVIO (selinexor). Karyopharm Therapeutics, Inc., Newton, MA, USA (2019). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf
10.
GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf). GlaxoSmithKline, Research Triangle Park, NC, USA (2020). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf
11.
Chari A, Vogl DT, Gavriatopoulou M et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381(8), 727–738 (2019).
• Describes efficacy and safety data for patients with triple-class refractory multiple myeloma treated with oral selinexor-dexamethasone.
12.
Lonial S, Lee HC, Badros A et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21(2), 207–221 (2020).
• Outlines the safety and activity of belantamab mafodotin in heavily pretreated patients with relapsed or refractory multiple myeloma (DREAMM-2).
13.
Rodriguez-Otero P, Ayers D, Cope S et al. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk. Lymphoma 62(10), 2482–2491 (2021).
14.
Moreau P, San Miguel J, Sonneveld P et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv52–iv61 (2017).
15.
Madduri D, Hagiwara M, Parikh K et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 17(5), 503–515 (2021).
16.
Jagannath S, Lin Y, Goldschmidt H et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 11(6), 116 (2021).
•• Describes a retrospective study (KarMMa-RW) comparing real-world outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma with patients treated with idecabtagene vicleucel in KarMMa.
17.
Davies F, Rodriguez-Otero P, Weisel K et al. A systematic literature review to assess efficacy of treatments in triple-class exposed relapsed and refractory multiple myeloma patients. HemaSphere 4(Suppl. 1), S476 (2020).
• A systematic review of studies evaluating the efficacy of treatments for triple-class exposed patients with relapsed and refractory myeloma.
18.
Blade Creixenti J, Mateos MV, Oriol A et al. HORIZON (OP-106) versus MAMMOTH: an indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus dexamethasone versus conventional agents. Blood 136(Suppl. 1), S2–S4 (2020).
19.
Suvannasankha A, Kapetanakis V, Prawitz T et al. Assessing efficacy via indirect comparison of single-agent belantamab mafodotin (belamaf; GSK2857916) in DREAMM-2 versus STORM or MAMMOTH studies in relapsed/refractory multiple myeloma (RRMM). Clin. Lymphoma Myeloma Leuk. 20(Suppl. 1), S300–S301 (2020).
20.
Costa LJ, Hari P, Kumar SK et al. Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of the STORM and MAMMOTH studies. Blood 134(Suppl. 1), S3125 (2019).
21.
Costa LJ, Lin Y, Martin TG et al. Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma. J. Clin. Oncol. 39(Suppl. 15), S8030 (2021).
22.
Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17(8), e328–e346 (2016).
23.
Cornell R, Parameswaran H, Tang S et al. Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). Clin. Lymphoma Myeloma Leuk. 19(Suppl. 10), e115–e116 (2019).
24.
Cornell RF, Gandhi UH, Lakshman A et al. Subsequent treatment outcomes of multiple myeloma refractory to CD38-monoclonal antibody therapy. Blood 132(Suppl. 1), S2015 (2018).
25.
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).
26.
Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia. 20(9), 1467–1473 (2006).
27.
Rajkumar SV, Harousseau JL, Durie B et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18), 4691–4695 (2011).
28.
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. National Institute for Health and Care Excellence (NICE) Decision Support Unit, Sheffield, UK (2016). Available at: http://nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf
29.
Signorovitch JE, Sikirica V, Erder MH et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940–947 (2012).
30.
Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int. J. Technol. Assess. Health Care. 35(3), 221–228 (2019).
31.
Cope S, Toor K, Popoff E et al. Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma. Value. Health 23(4), 441–450 (2020).
32.
Shah N, Ayers D, Davies FE et al. A matching-adjusted indirect comparison of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy versus conventional care in triple-class-exposed relapsed and refractory multiple myeloma. Blood 136(Suppl. 1), S6–S7 (2020).
•• Findings from the authors' previous analysis of efficacy outcomes for KarMMa versus MAMMOTH, which was based on shorter follow-up (13.3 months) data from KarMMa.
33.
Mehra M, Vogel M, Valluri S et al. Patient characteristics, treatment patterns and outcomes in patients with triple class refractory multiple myeloma. HemaSphere 4(Suppl. 1), S475–S476 (2020).
34.
Prawitz T, Popat R, Suvannasankha A et al. DREAMM-2: indirect comparisons of belantamab mafodotin vs. selinexor + dexamethasone and standard of care treatments in relapsed/refractory multiple myeloma. Adv. Ther. 38(11), 5501–5518 (2021).
Information & Authors
Information
Published In
Pages: 737 - 749
PubMed: 35485211
Copyright
© 2022 Nina Shah. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 2 March 2022
Accepted: 13 April 2022
Published online: 29 April 2022
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2022-0045
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Eric M. Ammann, Thomas Renaud, Bonnie W. Lau, Jenny Zhang, Trilok Parekh, Kathleen S. Gray, Xinke Zhang, Luciano J. Costa, Relative Effectiveness of Talquetamab Versus Real-World Physician’s Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From an Indirect Treatment Comparison, Clinical Lymphoma Myeloma and Leukemia, 10.1016/j.clml.2025.12.009, 26, 4, (e525-e535.e3), (2026).
- Lotte Delemarre, Isabelle Huys, Walter Van Dyck, Steven Simoens, Addressing clinical uncertainties in ATMP reimbursement: a review of methodological guidelines and European practice, Frontiers in Pharmacology, 10.3389/fphar.2026.1749386, 17, (2026).
- Melissa Alsina, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej J. Jakubowiak, Benjamin A. Derman, Aojun Li, Pingping Mao, Maeva Fincker, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesus G. Berdeja, Noopur Raje, Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study, Cancer Immunology Research, 10.1158/2326-6066.CIR-24-0527, 14, 4, (528-542), (2026).
- Cyrille Touzeau, Brea Lipe, Abdullah M. Khan, Binod Dhakal, Sandhya Nair, Jianming He, João Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M. Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noemí Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, Surbhi Sidana, Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma, Advances in Therapy, 10.1007/s12325-025-03308-2, 42, 10, (5023-5041), (2025).
- Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Eric Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Steve Peterson, Luciano J. Costa, Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 10.1016/j.clml.2024.08.003, 25, 2, (124-134.e5), (2025).
- Ning Lyu, Zahra Majd, Bilqees Fatima, Zhen Zeng, Hua Chen, Susan Abughosh, Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data, Cancer Treatment and Research Communications, 10.1016/j.ctarc.2025.100921, 43, (100921), (2025).
- Irene Strassl, CAR-T cell therapy for relapsed or refractory multiple myeloma in 2024—clinically available treatment options in Austria, memo - Magazine of European Medical Oncology, 10.1007/s12254-024-00996-4, 17, 4, (242-246), (2024).
- Dylan Maciel, Jeroen P. Jansen, Sven L. Klijn, Kevin Towle, Devender Dhanda, Bill Malcolm, Shannon Cope, Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma, Value in Health, 10.1016/j.jval.2024.04.017, 27, 8, (1012-1020), (2024).
- Zainul S. Hasanali, Beatrice Razzo, Sandra P. Susanibar-Adaniya, Alfred L. Garfall, Edward A. Stadtmauer, Adam D. Cohen, Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma, Hematology/Oncology Clinics of North America, 10.1016/j.hoc.2023.12.004, 38, 2, (383-406), (2024).
- Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Rosario Vicidomini, Naresh Poondla, Hamid Tanzadehpanah, Ashkan Dirbaziyan, Hanie Mahaki, Hamed Manoochehri, Naser Kalhor, Paola Dama, CAR T therapies in multiple myeloma: unleashing the future, Cancer Gene Therapy, 10.1038/s41417-024-00750-2, 31, 5, (667-686), (2024).
- See more